Flemming Ørnskov (born 1957/58) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma[2] since October 2019.
Flemming Ørnskov | |
|---|---|
 | |
| Born | 1957 or 1958 (age 65–66)[1] |
| Nationality | Danish |
| Alma mater | University of Copenhagen INSEAD Harvard University |
| Occupation(s) | CEO, Galderma |
He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel.[3] He previously worked for Bayer, Bausch & Lomb and Novartis.[2]
He is also the non-executive chairman of Waters Corporation, a position he's been holding since 2017.[4][5]
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[1]
Ørnskov led Galderma's IPO on the Zurich stock exchange on March 22, 2024, one of the biggest offerings in Europe in years and the biggest in Switzerland since 2017.[6][7] He declares Galderma plans to use the proceeds to pay down debt and invest in its pipeline.[8]
Awards
Top 100 Best-Performing CEOs in the World, 2015 - Harvard Business Review[9]
Top 25 Most Influential People in Biopharma Today, 2013 - Fierce Biotech[10]